Cargando…

Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK

INTRODUCTION: Large numbers of patients with type 2 diabetes receive treatment with a sodium-glucose co-transporter-2 inhibitor (SGLT2i). We investigated whether the cardiorenal preventative effects found in clinical trials are also seen in clinical practice where patient characteristics and adheren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez Perez, Antonio, Vizcaya, David, Sáez, Maria E, Lind, Marcus, Garcia Rodriguez, Luis A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Epidemiology/Health services research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814995/ https://www.ncbi.nlm.nih.gov/pubmed/36596641 http://dx.doi.org/10.1136/bmjdrc-2022-003072

Ejemplares similares

Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK
por: González-Pérez, Antonio, et al.
Publicado: (2021)

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
por: Nadkarni, Girish N., et al.
Publicado: (2017)

Initiating SGLT2 inhibitor therapy to improve renal outcomes for persons with diabetes eligible for an intensified glucose-lowering regimen: hypothetical intervention using parametric g-formula modeling
por: Takeuchi, Masato, et al.
Publicado: (2022)

Association of vitamin B(12) deficiency in people with type 2 diabetes on metformin and without metformin: a multicenter study, Karachi, Pakistan
por: Miyan, Zahid, et al.
Publicado: (2020)

Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy
por: Ren, Hongye, et al.
Publicado: (2023)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014)

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
por: Donnelly, Louise A., et al.
Publicado: (2020)

Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study
por: Pradhan, Richeek, et al.
Publicado: (2023)

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

Night Shift Work, Genetic Risk, and Type 2 Diabetes in the UK Biobank
por: Vetter, Céline, et al.
Publicado: (2018)

Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study
por: Au Yeung, Shiu Lun, et al.
Publicado: (2019)

Contribution of type 2 diabetes to all-cause mortality, cardiovascular disease incidence and cancer incidence in white Europeans and South Asians: findings from the UK Biobank population-based cohort study
por: Muilwijk, Mirthe, et al.
Publicado: (2019)

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
por: Shao, Shih-Chieh, et al.
Publicado: (2019)

Comparative effect of metformin versus sulfonylureas with dementia and Parkinson’s disease risk in US patients over 50 with type 2 diabetes mellitus
por: Newby, Danielle, et al.
Publicado: (2022)

Metformin and breast and gynecological cancer risk among women with diabetes
por: Soffer, Diana, et al.
Publicado: (2015)

Metformin Use in Prediabetes Among U.S. Adults, 2005–2012
por: Tseng, Eva, et al.
Publicado: (2017)

Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes
por: McEwen, Laura N., et al.
Publicado: (2022)

The risk of total mortality and cardiovascular mortality associated with impaired glucose regulation in Tayside, Scotland, UK: a record-linkage study in 214 094 people
por: Evans, Josie M M, et al.
Publicado: (2015)

Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2020)

Associations between grip strength and incident type 2 diabetes: findings from the UK Biobank prospective cohort study
por: Boonpor, Jirapitcha, et al.
Publicado: (2021)

Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine
por: Tuot, Delphine S., et al.
Publicado: (2015)

Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis
por: Ping, Fan, et al.
Publicado: (2020)

Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas
por: Chu, Patricia Y., et al.
Publicado: (2020)

Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes : Epidemiology and risk factors
por: Giorda, Carlo B., et al.
Publicado: (2008)

Sex Disparities in the Treatment and Control of Cardiovascular Risk Factors in Type 2 Diabetes
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2008)

Medication burden in the first 5 years following diagnosis of type 2 diabetes: findings from the ADDITION-UK trial cohort
por: Black, James A, et al.
Publicado: (2015)

Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study
por: Gordon, Jason, et al.
Publicado: (2018)

Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study
por: Sütő, Gábor, et al.
Publicado: (2021)

The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes
por: Lee, Alexandra K., et al.
Publicado: (2018)

Time trends in the incidence of clinically diagnosed type 2 diabetes and pre-diabetes in the UK 2009–2018: a retrospective cohort study
por: Pal, Kingshuk, et al.
Publicado: (2021)

Barriers and enablers to diabetic retinopathy screening: a cross-sectional survey of young adults with type 1 and type 2 diabetes in the UK
por: Prothero, Louise, et al.
Publicado: (2022)

Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis
por: Abolhassani, Nazanin, et al.
Publicado: (2023)

Inequalities in glycemic management in people living with type 2 diabetes mellitus and severe mental illnesses: cohort study from the UK over 10 years
por: Das-Munshi, Jayati, et al.
Publicado: (2021)

Use of metformin following a population-level intervention to encourage people with pre-diabetes to enroll in the National Diabetes Prevention Program
por: Hurst, Thomas E, et al.
Publicado: (2021)

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
por: Rabizadeh, Soghra, et al.
Publicado: (2019)

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
por: Vargas-Delgado, Ariana P., et al.
Publicado: (2023)

Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020)

Tissue inhibitor matrix metalloproteinase 1 and risk of type 2 diabetes in a Chinese population
por: Wang, Yeli, et al.
Publicado: (2020)

Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes
por: Ólafsdóttir, Arndís Finna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0bssk8m4kst4a1m2kfev2s81cp